InflaRx (NASDAQ:IFRX) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

InflaRx (NASDAQ:IFRX) had its price target upped by equities research analysts at Cantor Fitzgerald from $2.00 to $4.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 49.09% from the stock’s current price.

A number of other research firms have also recently weighed in on IFRX. Guggenheim reaffirmed a “buy” rating and set a $14.00 price objective on shares of InflaRx in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research report on Friday, March 27th. Finally, Oppenheimer initiated coverage on shares of InflaRx in a research note on Friday, April 24th. They issued an “outperform” rating and a $5.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $5.50.

InflaRx Stock Performance

Shares of IFRX stock traded up $0.10 during mid-day trading on Monday, reaching $2.68. 62,843 shares of the company’s stock traded hands, compared to its average volume of 1,068,823. The firm has a market capitalization of $193.95 million, a PE ratio of -3.75 and a beta of 2.42. InflaRx has a 12 month low of $0.71 and a 12 month high of $2.95. The firm has a 50 day moving average price of $1.19 and a two-hundred day moving average price of $1.13.

InflaRx (NASDAQ:IFRX) last released its earnings results on Thursday, May 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.08. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. As a group, equities analysts expect that InflaRx will post -0.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IFRX. Cubist Systematic Strategies LLC raised its position in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after buying an additional 7,616 shares during the last quarter. Boothbay Fund Management LLC increased its holdings in InflaRx by 10.8% in the 3rd quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock valued at $235,000 after acquiring an additional 17,056 shares during the last quarter. Concurrent Investment Advisors LLC increased its holdings in InflaRx by 56.9% in the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after acquiring an additional 19,200 shares during the last quarter. Eversept Partners LP lifted its stake in InflaRx by 1.5% in the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock worth $1,775,000 after purchasing an additional 26,677 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of InflaRx by 29.1% during the 3rd quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock valued at $253,000 after purchasing an additional 42,489 shares during the last quarter. 42.39% of the stock is currently owned by institutional investors.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.